Median Technologies Secures up to €10 million equity line completed with IRIS to enable 2025 EIB loan

24 janv. 2025

Median Technologies secures up to €10 million in fresh funding from IRIS, underscoring IRIS’s pivotal role in accelerating the company’s AI-driven cancer diagnostics.

Sophia Antipolis, France – jan 24, 2025 – Median Technologies a leading developer of eyonis™, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnostics, and a globally leading provider of AI analyses and imaging services for oncology drug developers announces up to €10 million equity line completed with IRIS to enable 2025 EIB loan.

Download English Press Release

Télécharger le communiqué de presse en français